Drugs
Milberg Weiss Bershad Hynes & Lerach LLP, a prominent law firm specializing in class actions, announced a lawsuit against Schein Pharmaceutical, Inc. alleging violations of the Securities Act of 1933. The complaint, filed on September 14, 1998, in the United States District Court for the District of New Jersey, seeks
Drugs
R.E.D. Laboratories NV, a Belgian biotechnology company, has announced an expanded research collaboration with Hemispherx Biopharma, Inc. to develop and commercialize diagnostic tests for Chronic Fatigue Syndrome (CFS) and other chronic immune and viral diseases. This collaboration aims to fully define the importance of the antiviral enzyme RNase
Drugs
A class action lawsuit has been commenced against Schein Pharmaceutical, Inc. on behalf of all individuals who purchased the company's common stock in its initial public offering on April 9, 1998. The lawsuit claims that Schein and other defendants violated securities laws by making material misstatements and omissions
Drugs
Eisai Inc., a research-based human healthcare company, has successfully implemented the QAD MFG/PRO enterprise resource planning (ERP) system at its Research Triangle Park, North Carolina Pharmaceutical Manufacturing Division. The implementation was led by The Hunter Group, an international leader in planning and implementing ERP applications. The QAD MFG/PRO
Drugs
Warner-Lambert Company, a Morris Plains, New Jersey-based pharmaceutical company, has awarded Base Ten Systems, Inc. a $1.1 million contract to provide BASE10(TM) Manufacturing Execution Systems (MES) for its pharmaceutical manufacturing facilities. The systems will be installed according to a rollout plan concluding in the year 2000. This contract
Drugs
In a unique partnership with the Tunbridge Wells Equitable Friendly Society, Mirror Money ran a competition where triplets Christopher, Mark, and Philip Lilly, and their brother James, 13, received a special tenth birthday present - a cheque for pounds 1,709. This amount represents the accumulated savings from the Baby
Drugs
Affymetrix, Inc., a leader in genetic analysis, has partnered with Eli Lilly and Company to provide broad access to Affymetrix's GeneChip arrays, instrumentation, and software for use in research and development activities. This three-year agreement will enable Lilly to monitor gene expression, a crucial step in the drug
Drugs
A lawsuit was filed in the United States District Court for the Western District of Washington on behalf of individuals who purchased Sonus Pharmaceuticals, Inc. common stock between September 24, 1996, and June 8, 1998. The complaint alleges that Sonus and certain of its officers and directors participated in a
Drugs
The Seattle law firm of Hagens Berman has filed a class action lawsuit against Sonus Pharmaceuticals, Inc. and certain of its officers and directors for alleged violations of federal securities laws. The lawsuit, filed in the United States District Court for the Western District of Washington, claims that Sonus and
Drugs
MorphoSys AG, a leading developer of therapeutic monoclonal antibodies, and LeukoSite Inc., a biotechnology company focused on developing drugs for autoimmune and inflammatory diseases, have announced a two-year collaboration to discover and develop therapeutic monoclonal antibodies for inflammatory and autoimmune disorders. The partnership combines MorphoSys' technology for rapidly generating
Drugs
A team of five industry leaders, including Genencor International, Eastman Chemical Company, Electrosynthesis Company Inc., MicroGenomics Inc., and Argonne National Laboratory, has achieved a significant milestone in developing new methods to manufacture chemicals from renewable resources. The first target chemical, ascorbic acid (vitamin C), has a worldwide market of approximately
Drugs
Bio-Imaging Technologies, Inc., a biomedical information technology and services company, has entered into a contract with Pharmacyclics, Inc. to provide medical image processing and digital image management services for a phase III clinical trial of Pharmacyclics' Gd-Tex radiation sensitizer. The contract is valued at approximately $1.1 million and
